Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Haematological and Immunological Effect After New Direct Acting Antiviral Drugs in Chronic Hepatitis c Virus Egyptian Patients

Trial Profile

Assessment of Haematological and Immunological Effect After New Direct Acting Antiviral Drugs in Chronic Hepatitis c Virus Egyptian Patients

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 25 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top